Heartbeam Inc. Warrant (BEATW)
Stock · NASDAQ · Health Care
$0.0031as of 10/16/2026
Price chart
Fundamentals
- 1-day range
- $0.0031$0.0097
- Market cap
- $1.19M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 0.49
- Avg. volume
- —
52-week range
$0.005$0.5601
Heartbeam Inc. Warrant Competitors
Chosen by industry and closest market cap.
- BEATWHeartbeam Inc. Warrant$0.0031▼ 65.56%Market cap $1.19MP/E —$0.005$0.5601
- BJDXBluejay Diagnostics Inc. Common Stock$0.745▼ 4.36%Market cap $1.19MP/E —$0.755$16.68
- VTAKCatheter Precision Inc. Common Stock$0.84▼ 14.29%Market cap $977.1KP/E —$0.82$30.6
- PFSAProfusa Inc. Common Stock$0.931▼ 12.99%Market cap $686.5KP/E —$1.25$3,000
- AEMDAethlon Medical Inc. Common Stock$5.15▼ 2.28%Market cap $1.96MP/E —$1.41$35.95
- TNONTenon Medical Inc. Common Stock$2.7▼ 7.22%Market cap $1.99MP/E —$2.4$50.4
- TNONWTenon Medical Inc. Warrant$0.0054▼ 8.47%Market cap $85.3KP/E —$0.0038$0.043
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BEATW Heartbeam Inc. Warrant | $1.19M | — | $0.0031 | ▼ 65.56% | $0.005$0.5601 |
| BJDX Bluejay Diagnostics Inc. Common Stock | $1.19M | — | $0.745 | ▼ 4.36% | $0.755$16.68 |
| VTAK Catheter Precision Inc. Common Stock | $977.1K | — | $0.84 | ▼ 14.29% | $0.82$30.6 |
| PFSA Profusa Inc. Common Stock | $686.5K | — | $0.931 | ▼ 12.99% | $1.25$3,000 |
| AEMD Aethlon Medical Inc. Common Stock | $1.96M | — | $5.15 | ▼ 2.28% | $1.41$35.95 |
| TNON Tenon Medical Inc. Common Stock | $1.99M | — | $2.7 | ▼ 7.22% | $2.4$50.4 |
| TNONW Tenon Medical Inc. Warrant | $85.3K | — | $0.0054 | ▼ 8.47% | $0.0038$0.043 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 554.0K
- Total value held
- $66.5K
- Institutional holders
- 6
Top holders this quarter
- Unknown500.0K
- Unknown16.6K
- Unknown16.0K
- Unknown11.9K
- Unknown7.5K
- Unknown2.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
HeartBeam Warrant Rises on FDA Breakthrough Designation
HeartBeam received FDA Breakthrough Device Designation for its heart attack assessment tool, a significant regulatory milestone. This news drove a sharp increase in trading activity and stock price. The warrant is currently trading near its 52-week low, but the volume spike reflects strong market reaction to this positive development.
HeartBeam Warrant Rises on FDA Breakthrough Designation. HeartBeam received FDA Breakthrough Device Designation for its heart attack assessment tool, a significant regulatory milestone. This news drove a sharp increase in trading activity and stock price. The warrant is currently trading near its 52-week low, but the volume spike reflects strong market reaction to this positive development.